|
Turkish Society of Cardiology
Young Cardiologists
President
Dr. Muzaffer Değertekin
Coordinator for the
Board of Directors
Dr. Ertuğrul Okuyan
Coordinator for the
Board of Directors
Dr. Can Yücel Karabay
Members
Dr. Adem Aktan
Dr. Gülşah Aktüre
Dr. Bayram Arslan
Dr. İnanç Artaç
Dr. Ahmet Oğuz Aslan
Dr. Görkem Ayhan
Dr. Ahmet Anıl Başkurt
Dr. Özkan Bekler
Dr. Oğuzhan Birdal
Dr. Yusuf Bozkurt Şahin
Dr. Serkan Bulgurluoğlu
Dr. Ümit Bulut
Dr. Veysi Can
Dr. Mustafa Candemir
Dr. Murat Çap
Dr. Göksel Çinier
Dr. Ali Çoner
Dr. Yusuf Demir
Dr. Ömer Furkan Demir
Dr. Murat Demirci
Dr. Ayşe İrem Demirtola Mammadli
Dr. Süleyman Çağan Efe
Dr. Mehmet Akif Erdöl
Dr. Kubilay Erselcan
Dr. Kerim Esenboğa
Dr. Duygu Genç
Dr. Kemal Göçer
Dr. Elif Güçlü
Dr. Arda Güler
Dr. Duygu İnan
Dr. Hasan Burak İşleyen
Dr. Muzaffer Kahyaoğlu
Dr. Sedat Kalkan
Dr. Yücel Kanal
Dr. Özkan Karaca
Dr. Ahmet Karaduman
Dr. Mustafa Karanfil
Dr. Ayhan Kol
Dr. Fatma Köksal
Dr. Mevlüt Serdar Kuyumcu
Dr. Yunus Emre Özbebek
Dr. Ahmet Özderya
Dr. Yasin Özen
Dr. Ayşenur Özkaya İbiş
Dr. Çağlar Özmen
Dr. Selvi Öztaş
Dr. Hasan Sarı
Dr. Serkan Sivri
Dr. Ali Uğur Soysal
Dr. Hüseyin Tezcan
Dr. Nazlı Turan
Dr. Berat Uğuz
Dr. Örsan Deniz Urgun
Dr. İdris Yakut
Dr. Mustafa Yenerçağ
Dr. Mehmet Fatih Yılmaz
Dr. Yakup Yiğit
Dr. Mehmet Murat Yiğitbaşı
Bulletin Editors
Dr. Muzaffer Değertekin
Dr. Can Yücel Karabay
Dr. Muzaffer Kahyaoğlu
Contributors
Dr. Ahmet Caner Canpolat
Dr. Aysu Oktay
Dr. Hadi Verdiyev
Dr. Kemal Göçer
Dr. Mehmet Altunova
Dr. Mehmet Murat Yiğitbaşı
Dr. Merve Kapçık
Dr. Muhammed Ali Söyler
Dr. Muhammet Ali Ekiz
Dr. Mustafa Yenerçağ
Dr. Mustafa Yılmaz
Dr. Özkan Karaca
Dr. Ramazan Furkan Demirkıran
Dr. Seda Kurat Güldoğmuş
Dr. Sefa Sarı
Dr. Selim Süleyman Sert
Dr. Serkan Bulguroğlu
Dr. Ülkü Nur Koç
Dr. Yücel Kanal
|
| |
|
|
|
BIOADAPTOR-RCT: Three-Year Clinical Follow-Up ResultsTürk Kardiyoloji Derneği Genç Kardiyologlar Bülteni - BIOADAPTOR-RCT: Three-Year Clinical Follow-Up Results (Dr. Ramazan Furkan Demirkıran)Prepared by: Dr. Ramazan Furkan Demirkıran
Name of the Study: BIOADAPTOR-RCT: Three-Year Clinical Follow-Up Results
Presented at: EuroPCR 2025
Introduction
This randomized controlled trial compares the sirolimus-eluting coronary bioadaptor system (DynamX®, Elixir Medical) with a zotarolimus-eluting drug-eluting stent (DES). Conducted at 34 sites across Japan, Europe, and New Zealand, the study enrolled a total of 445 patients.
Objective
The study aims to evaluate whether the DynamX bioadaptor offers superior long-term clinical outcomes by reducing device-related adverse events, specifically target lesion failure (TLF), compared to conventional DES.
Methodology
- Participants were randomized 1:1 to receive either the DynamX bioadaptor (n=223) or the Resolute Onyx DES (n=222)
- Primary endpoint: TLF at 1 year (non-inferiority)
- Secondary endpoints: percent diameter stenosis (%DS), vessel pulsatility, target vessel failure (TVF)
- Imaging methods included QCA, IVUS, and OCT
- Follow-up completion at 3 years: 99%
Key Findings at 3-Year Follow-Up
- TLF rate: 2.7% in the bioadaptor group vs. 7.2% in the DES group (p=0.030)
- Cardiovascular death: 0.5% with bioadaptor vs. 3.2% with DES (p=0.033)
- Lower rates of target vessel MI and clinically driven TLR were also observed in the bioadaptor group
- In LAD lesions: TLF was 2.7% (bioadaptor) vs. 10.6% (DES), p=0.019
Mechanism and Design Advantages of the Bioadaptor
- Made of three CoCr sinusoidal strands held together by a bioresorbable polymer that degrades after 6 months
- Once unlocked, the strands restore vascular dynamics: compliance, pulsatility, and adaptive remodeling
- This physiological adaptability minimizes long-term complications seen with rigid stents
Conclusions
The study provides robust evidence that the DynamX bioadaptor leads to significantly fewer adverse events than DES over a 3-year period. The ability of the bioadaptor to preserve vascular physiology and accommodate vessel remodeling translates into durable and superior clinical outcomes, especially in critical lesions like LAD.
|
